CCL2 and idiopathic pulmonary fibrosis: The potential application of CCL2 as a clinical biomarker of IPF seems to be limited by its low specificity; its serum concentrations are higher in connective tissue lung diseases than in IPF, and common nonrespiratory diseases such as atherosclerosis may raise levels, acting as a confounding factor [38, 39].